Otis Gowdy, MD
Nephrology · Meridian, MSNPI 1992782544
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (50.7%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Fresenius USA Marketing, Inc. accounts for 75.2% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2022 at $4,599 and has fallen 88.4% since, to $535 in 2025. Among nephrology clinicians in MS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 125 payments — averaging $92.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Fresenius USA Marketing, Inc.$9K
- AstraZeneca$690
- Bayer$569
- Akebia Therapeutics Inc$444
- Aurinia Pharma U.S., Inc.$317
- Novartis$254
- plus $588 from 13 others
What the payments were for
- Consulting fees$5,86351%
- Travel & lodging$1,79015%
- Food & beverage$3,86033%
- Education$460%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Fresenius USA Marketing, Inc. | 9 | $8,697 |
| AstraZeneca | 29 | $690 |
| Bayer | 24 | $569 |
| Akebia Therapeutics Inc | 13 | $444 |
| Aurinia Pharma U.S., Inc. | 12 | $317 |
| Novartis | 8 | $254 |
| Vifor Pharma, Inc. | 7 | $147 |
| Otsuka America Pharmaceutical, Inc. | 3 | $63 |
| Lilly USA, LLC | 3 | $58 |
| Amgen(2 entities) | 2 | $51 |
| Ardelyx, Inc. | 2 | $44 |
| Daiichi Sankyo Inc. | 2 | $41 |
| Bard Peripheral Vascular, Inc. | 2 | $38 |
| Boehringer Ingelheim | 2 | $35 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
| AbbVie | 2 | $23 |
| Calliditas Therapeutics US Inc. | 1 | $23 |
| Mallinckrodt Hospital Products Inc. | 1 | $21 |
| Travere Therapeutics, Inc. | 2 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,558 in reported general payments places this provider in the 95th percentile of 105 nephrology providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 102 | $227,954 |
| AuryxiaFerric Citrate | 86 | $136,069 |
| FarxigaDapagliflozin Propanediol | 74 | $50,471 |
| FosrenolLanthanum Carbonate | 13 | $18,770 |
| Sevelamer Carbonate | 102 | $15,521 |
| Lanthanum Carbonate | 18 | $13,412 |
| JardianceEmpagliflozin | 24 | $12,854 |
| EliquisApixaban | 11 | $9,860 |
| LinzessLinaclotide | 14 | $8,845 |
| KerendiaFinerenone | 13 | $8,099 |
| Calcium Acetate | 45 | $4,466 |
| Midodrine Hcl | 26 | $2,351 |
| Nifedipine ErNifedipine | 55 | $1,207 |
| Carvedilol | 89 | $1,011 |
| Hydralazine Hcl | 69 | $993 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Fresenius USA Marketing, Inc.Velphoro | $8,697 | $227,954102 claims |
| Akebia Therapeutics IncAuryxia | $444 | $136,06986 claims |
| AstraZenecaFarxiga | $690 | $50,47174 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Fosrenol | $24 | $18,77013 claims |
| Boehringer IngelheimJardiance | $35 | $12,85424 claims |
| AbbVieLinzess | $23 | $8,84514 claims |
| BayerKerendia | $569 | $8,09913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 105 nephrology providers in Mississippi.
Other nephrology in Meridian
- John AndyMeridian$2K
- Robert ClarkMeridian$2K
- Alisha ParkerMeridian$2K
- Mohit AhujaFlowood$427K
- Padam HirachanNatchez$29K
- Brian RifkinHattiesburg$23K
- Richard MillerBrookhaven$10K
- Thomas WooldridgeTupelo$8K
- Steven WagnerFlowood$6K
- John Martin LeeTupelo$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.